Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Proof.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
Comment by Inthepezon Sep 28, 2021 10:32am
92 Views
Post# 33930205

RE:Proof.

RE:Proof.I know you love the attention I’m giving you. But you posting a pic of daddy’s car, eclipses any shares that you or may not have bought.

But since you brought it up, Why don’t you post your shares? It’ll only take a few seconds. No excuses.

fyi I don’t believe it’s car clown. We need more proof lmao

Rarbar99 wrote: Pez, I told you I owned $25K worth of shares. You didn't believe me, so I showed you a photo of my $250K car instead with my username on the dashboard.

that shut you up real quick, you never spoke about my shares ever again.

now It's your turn. You don't need to show me your car, just show us your portfolio and show us your average price. It will take a few seconds to do this, so don't try and make an excuse.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities